Literature DB >> 15052245

Baseline/post-nitrate Tc-99m tetrofosmin mismatch for the assessment of myocardial viability in patients with severe left ventricular dysfunction: comparison with baseline Tc-99m tetrofosmin scintigraphy/FDG PET imaging.

Assuero Giorgetti1, Paolo Marzullo, Gianmario Sambuceti, Simona Di Quirico, Annette Kusch, Patrizia Landi, Piero Antonio Salvadori, Patrizia Pisani, Antonio L'abbate.   

Abstract

BACKGROUND: Positron emission tomography (PET) flow/metabolic mismatch is considered the nuclear medicine gold standard for the assessment of myocardial viability. The aim of this study was to investigate whether baseline/nitrate technetium 99m tetrofosmin single photon emission computed tomography (SPECT) mismatch may provide equivalent clinical information. METHODS AND
RESULTS: We studied 23 patients (aged 62 +/- 10 years, 19 men) with previous myocardial infarction (16 anterior, 4 inferior, and 3 anterior plus inferior) and postischemic heart failure (gated SPECT [G-SPECT] ejection fraction, 26% +/- 8%). All patients underwent Tc-99m tetrofosmin G-SPECT at rest and after nitrates (intravenous isosorbide dinitrate, 0.2 mg/mL, 10 mL/h) as well as a fluorine 18 fluoro-2-deoxy-d-glucose (FDG) PET scan. Regional wall motion analysis was performed with quantitative G-SPECT (QGS). Myocardial dysfunction was defined as a regional QGS score of 2 or greater. Regional perfusion was assessed by quantitative perfusion score (QPS) providing percent Tc-99m tetrofosmin uptake in a 20-segment model. Semiquantitative analysis of FDG uptake was performed by use of polar maps generated by Siemens ECAT HR + software. In areas with a perfusion rate lower than 80%, PET viability was identified by a normalized FDG percent uptake/baseline Tc-99m tetrofosmin percent uptake ratio greater than 1.2. We analyzed 460 segments; 298 (64%) were dysfunctional by QGS analysis. Of these, 170 were viable by PET imaging whereas 128 were nonviable. Regional Tc-99m tetrofosmin uptake was higher in viable than in nonviable segments both at rest (60% +/- 24% vs 42% +/- 12%, P <.01) and after nitrates (67% +/- 20% vs 41% +/- 18%, P <.01). According to receiver operating characteristic curve analysis, a cutoff value of 63% for resting as well as post-nitrate G-SPECT provided the highest diagnostic accuracy for the detection of myocardial viability (67% and 72% at rest and after nitrates, respectively). When the same algorithm used for the comparison with PET (normalized nitrate percent uptake/baseline percent uptake) was applied to G-SPECT, we obtained the highest agreement with PET (accuracy, 93%; sensitivity, 95%; specificity, 92%).
CONCLUSIONS: In patients with severe left ventricular dysfunction, perfusion data alone, both at rest and after nitrates, do not allow an accurate estimate of myocardial viability. In dysfunctioning segments, the analysis of rest/post-nitrate Tc-99m tetrofosmin mismatch provides results similar to those obtained by PET flow/metabolic mismatch.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052245     DOI: 10.1016/j.nuclcard.2003.12.011

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  31 in total

1.  Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease.

Authors:  J vom Dahl; C Altehoefer; F H Sheehan; P Buechin; G Schulz; E R Schwarz; K C Koch; R Uebis; B J Messmer; U Buell; P Hanrath
Journal:  J Nucl Med       Date:  1997-05       Impact factor: 10.057

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability?

Authors:  R S Beanlands; F Dawood; W H Wen; P R McLaughlin; J Butany; G D'Amati; P P Liu
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

4.  Nitrate administration to enhance the detection of myocardial viability by technetium-99m tetrofosmin single-photon emission tomography.

Authors:  A Flotats; I Carrió; M Estorch; L Bernà; A M Catafau; C Marí; M Ballester
Journal:  Eur J Nucl Med       Date:  1997-07

5.  Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization.

Authors:  M J Knuuti; M Saraste; P Nuutila; R Härkönen; U Wegelius; A Haapanen; J Bergman; M Haaparanta; T Savunen; L M Voipio-Pulkki
Journal:  Am Heart J       Date:  1994-04       Impact factor: 4.749

6.  Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction.

Authors:  R Sciagrà; M Pellegri; A Pupi; L Bolognese; G Bisi; V Carnovale; G M Santoro
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

7.  Quantitative analysis of technetium 99m 2-methoxyisobutyl isonitrile single-photon emission computed tomography and isosorbide dinitrate infusion in assessment of myocardial viability before and after revascularization.

Authors:  S T Li; X J Liu; Z L Lu; R F Shi; X D Zhu; W Q Chen; Q W Wu; Y Z Liu
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

8.  Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization.

Authors:  K Yoshida; K L Gould
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

9.  Regional blood flow, oxidative metabolism, and glucose utilization in patients with recent myocardial infarction.

Authors:  J Czernin; G Porenta; R Brunken; J Krivokapich; K Chen; R Bennett; A Hage; C Fung; J Tillisch; M E Phelps
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

10.  Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease.

Authors:  G Lucignani; G Paolini; C Landoni; M Zuccari; G Paganelli; L Galli; G Di Credico; G Vanoli; C Rossetti; M A Mariani
Journal:  Eur J Nucl Med       Date:  1992
View more
  6 in total

1.  Comparison of nitrate augmented Tc-99m tetrofosmin gated SPECT imaging with FDG PET imaging for the assessment of myocardial viability in patients with severe left ventricular dysfunction.

Authors:  Senthil Raja; Baljinder Singh; Manoj Kumar Rohit; Kuruva Manohar; Raghava Kashyap; Anish Bhattacharya; B R Mittal
Journal:  J Nucl Cardiol       Date:  2012-08-08       Impact factor: 5.952

2.  Myocardial imaging with 99mTc-Tetrofosmin: Influence of post-stress acquisition time, regional radiotracer uptake, and wall motion abnormalities on the clinical result.

Authors:  Assuero Giorgetti; Annette Kusch; Mirta Casagranda; Irene D'Aragona Tagliavia; Paolo Marzullo
Journal:  J Nucl Cardiol       Date:  2009-12-15       Impact factor: 5.952

3.  Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-10-01

4.  Incremental prognostic value of cardiac single-photon emission computed tomography after nitrate administration in patients with ischemic left ventricular dysfunction.

Authors:  Laura Evangelista; Wanda Acampa; Mario Petretta; Adele Ferro; Francesca Ricci; Luca Luongo; Stefania Daniele; Giorgio Punzo; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

5.  Diagnostic value of SPECT, PET and PET/CT in the diagnosis of coronary artery disease: A systematic review.

Authors:  M Al Moudi; Z Sun; N Lenzo
Journal:  Biomed Imaging Interv J       Date:  2011-04-01

Review 6.  Practical Implications of Myocardial Viability Studies.

Authors:  Wilter Dos Santos Ker; Thais Helena Peixoto Nunes; Marcelo Souto Nacif; Claudio Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2018-03       Impact factor: 2.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.